BioNTech keeps focus on mRNA cancer therapies despite trial misses
The company reaffirmed its mRNA oncology strategy on its third-quarter earnings call.
Read at GenomeWeb โFull coverage ยท 6 outlets
- GenomeWeb ยท lead
- TradingViewBioNTech Q3 Earnings Call Highlights
- Yahoo FinanceBioNTech (BNTX) Is Down 7.0% After mRNA Cancer Trial Misses PFS Goal Has The Bull Case Changed?
- BioPharma DiveBioNTech mRNA cancer immunotherapy misses first objective in key study
- ad-hoc-news.deBioNTech's Oncology Ambitions Face a Reckoning as BNT113 Misses Its First Hurdle
- KslBioNTech's mRNA cancer therapy misses first goal in head and neck trial